Basic Information
| LncRNA/CircRNA Name | lncRNA-RP11-317J10.2 |
| Synonyms | NA |
| Region | GRCh38_8:85441851-85464915 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR |
| Sample | colorectal cancer tissues, cell lines (NCM460, HT-29, HCT116, SW480, SW620 and LoVo) |
| Expression Pattern | down-regulated |
| Function Description | LncRNA-RP11-317J10.2 is downregulated in CRC and decreased expression is significantly associated with advanced tumor stage, larger tumor size and poor prognosis. RNA interference-mediated knockdown of lncRNA-RP11-317J10.2 in CRC cells promotes G1-to-S cell cycle transition, enhances invasiveness and facilitates cell growth in vitro and in mouse tumor xenograft models. Cyclin D1 was upregulated by lncRNA-RP11-317J10.2 knockdown, and co-expression of cyclin D1-targeting siRNA abrogates the pro-tumorigenic effects of lncRNA-RP11-317J10.2 knockdown.over-expression of PIWIL3 and miR-367-3p together with OIP5-AS1 knockdown produced the smallest xenograft volume in contrast to their respective single application, contributing to the longest survival. |
| Pubmed ID | 29073791 |
| Year | 2017 |
| Title | Downregulation of LncRNA-RP11-317J10.2 promotes cell proliferation and invasion and predicts poor prognosis in colorectal cancer. |
External Links
| Links for lncRNA-RP11-317J10.2 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |